Abeona Therapeutics Q2 net income beats estimates on PRV sale, sees profitability in H1 2026

Abeona Therapeutics

14/08/2025 12:41

Overview

Abeona Q2 net income of $108.8 mln beats analyst expectations, per LSEG data

Adjusted EPS of $1.71 beats estimates, driven sale of Rare Pediatric Disease priority review voucher (PRVsale)

ZEVASKYN U.S. launch on track and first patient treatment expected in Q3

Says with Abeona transitioning into a commercial organization,  some manufacturing and development costs reclassified from R&D expense to inventory or SG&A expenses.

Outlook

Abeona expects first ZEVASKYN treatment in Q3

Company anticipates profitability in 1H 2026

Company plans to scale ZEVASKYN supply to 10 patients/month by mid-2026

Result Drivers

FDA APPROVAL - ZEVASKYN received FDA approval in April 2025 for treating RDEB, marking a key milestone for Abeona

STRONG PATIENT INTEREST - High demand for ZEVASKYN with multiple patients identified and progressing towards treatment, per CEO Vish Seshadri

INSURANCE COVERAGE - Positive insurance coverage established with major national and regional payers, facilitating broad patient access

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
Beat
$1.71
-$0.39 (5 Analysts)
Q2 Net Income
Beat
$108.83 mln
-$19.40 mln (5 Analysts)
Q2 Income From Operations
Miss
-$22.79 mln
-$19.30 mln (6 Analysts)
Q2 Cash & Investments
$225.90 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Abeona Therapeutics Inc is $20.00, about 67.2% above its August 13 closing price of $6.56

Press Release: ID:nGNX2Lz1Sj

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)